相关实验视频

Updated: May 6, 2026

Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People

Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People

Published on: July 5, 2017

在老年肥胖患者中,利拉格卢提德是否安全有效? : 一个单一的中心体验体验

Alihan Oral¹, Celalettin Küçük², Yunus Kayalar³

¹Biruni University, Medical Faculty, Internal Medicine Department, Istanbul, Turkey.

|April 21, 2025

概括

利拉古胺在肥胖的老年人中有效降低体重,在24周内观察到显著的体重减轻. 这种治疗在这个人群中是安全和耐受的,恶心是主要的副作用.

科学领域:

老年学是一门学科.
内分泌学在内分泌学.
公共卫生公共卫生

背景情况:

全球肥胖率的上升影响所有年龄组,包括老年人.
在之前的试验中,利拉格卢提德已在老年人减肥方面表现出有效性.
老年人肥胖与各种并发症有关,需要有效的治疗选择.

研究的目的:

评估利拉格卢提德在肥胖的老年患者中促进减肥的有效性.
在这个人口群体中识别和记录与利拉格卢提德治疗相关的不良影响.
评估liraglutide在老年肥胖管理中的安全性和有效性.

主要方法:

追溯队列研究涉及32名年龄在60岁及以上的肥胖患者 (BMI≥27或≥30).
患者接受了利拉格卢提德治疗,数据收集时间为2023年9月至2024年9月.
人类测量和代谢参数被记录下来,并对体重和不良事件进行监测.

主要成果:

观察到显著的体重减轻:第4周减轻5.96%,第8周减轻10.06%,第12周减轻13.85%,第24周减轻15.80% (P < .0001).
到第24周,100%的患者实现了>5%和>10%的初始体重减轻.
恶心是最常见的不良反应;没有报告胰腺炎.

结论:

利拉格卢提德是一种有效的治疗老年人肥胖的方法.
这种药物在这个人群中显示出良好的安全性,并具有可控的副作用.
研究结果支持使用利拉格卢提德用于老年肥胖症的体重管理.

关键词:

利拉格卢提德 (liraglutide) 是一种葡萄糖类药物.肥胖肥胖肥胖肥胖肥胖肥胖肥胖肥胖年龄较大的成年人.

更多相关视频

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health

Published on: December 1, 2023

相关概念视频

Drug Dosing: Obese Patients

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...

Drug Dosing: Geriatric Patients

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...